Clinical trial
Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before…
NCT00288002 · GBG Forschungs GmbH, Other · Completed
Key facts
| NCT number | NCT00288002 |
|---|---|
| Title | Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer |
| Official title | A Randomized Phase III Study Exploring the Efficacy of Capecitabine Given Concomitantly or in Sequence to EC-Doc With or Without Trastuzumab as Neoadjuvant Treatment of Primary Breast Cancer |
| Lead sponsor | GBG Forschungs GmbH, Other |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Biological, Drug, Procedure |
| Interventions | trastuzumab, capecitabine, cyclophosphamide, docetaxel, epirubicin hydrochloride, adjuvant therapy, conventional surgery, neoadjuvant therapy |
| Enrollment | 1,500 |
| Start date | Jan 1, 2005 |
| First posted | Feb 7, 2006 |
| Last update posted | Aug 26, 2013 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: